Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Logerfo. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael Logerfo has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SGNT / Sagent Pharmaceuticals, Inc. President, CLO 53,292
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Logerfo. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Michael Logerfo as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2016-02-26 2016-02-25 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -402 53,292 -0.75 14.58 -5,861 776,997
2016-02-23 2016-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -486 53,694 -0.90 14.61 -7,100 784,469
2016-02-23 2016-02-21 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -744 54,180 -1.35 14.61 -10,870 791,570
2016-02-22 2016-02-18 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -634 54,924 -1.14
2016-01-05 2015-12-31 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -924 55,558 -1.64 15.85 -14,645 880,594
2015-05-13 2015-05-11 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -2,759 10,000 -21.62
2015-05-13 2015-05-11 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,759 56,482 5.14 4.31 11,891 243,437
2015-04-01 2015-03-30 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
A - Award 5,480 53,723 11.36
2015-02-27 2015-02-25 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
A - Award 8,208 8,208
2015-02-27 2015-02-25 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
A - Award 4,420 48,243 10.09
2015-02-24 2015-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -429 43,823 -0.97 28.50 -12,226 1,248,956
2015-02-24 2015-02-21 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -637 44,252 -1.42 28.50 -18,154 1,261,182
2015-02-20 2015-02-18 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -581 44,889 -1.28 27.22 -15,815 1,221,879
2014-12-30 2014-12-30 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
G - Gift -300 45,470 -0.66
2014-07-29 2014-07-25 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -12,759 0 -100.00
2014-07-29 2014-07-25 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,759 45,770 38.65 4.31 54,991 197,269
2014-02-28 2014-02-27 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -2,021 33,011 -5.77 21.43 -43,310 707,426
2014-02-24 2014-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -441 35,032 -1.24 21.75 -9,592 761,946
2014-02-24 2014-02-21 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -590 35,473 -1.64 21.84 -12,886 774,730
2014-02-24 2014-02-20 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -20,000 0 -100.00
2014-02-24 2014-02-20 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -3,894 36,063 -9.75 21.78 -84,811 785,452
2014-02-24 2014-02-20 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 20,000 39,957 100.22 4.23 84,600 169,018
2014-02-24 2014-02-20 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -4,638 19,957 -18.86 22.05 -102,268 440,052
2014-02-19 2014-02-18 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
A - Award 10,638 10,638
2014-02-19 2014-02-18 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
A - Award 5,952 24,595 31.93
2013-12-26 2013-12-24 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
G - Gift -1,400 18,643 -6.98
2013-12-26 2013-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
F - Taxes -506 20,043 -2.46 16.85 -8,526 337,725
2013-02-25 2013-02-21 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
A - Award 12,067 12,067
2013-02-25 2013-02-21 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
A - Award 6,991 20,549 51.56
2012-12-31 2012-12-28 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
G - Gift -1,300 13,558 -8.75
2012-12-13 2012-12-12 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
G - Gift -3,000 14,858 -16.80
2012-11-21 2012-11-20 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -4,243 19,999 -17.50
2012-11-21 2012-11-20 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,243 17,858 31.16 4.23 17,948 75,539
2012-11-20 2012-11-19 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -6,867 13,615 -33.53 14.64 -100,533 199,324
2012-11-20 2012-11-16 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -2,271 20,482 -9.98 14.68 -33,338 300,676
2012-11-16 2012-11-15 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -17,338 0 -100.00
2012-11-16 2012-11-15 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -9,000 22,753 -28.34 14.38 -129,420 327,188
2012-11-16 2012-11-15 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 17,338 31,753 120.28 4.23 73,340 134,315
2012-11-16 2012-11-14 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
M - Exercise -1,800 17,338 -9.41
2012-11-16 2012-11-14 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -1,000 14,415 -6.49 14.56 -14,560 209,882
2012-11-16 2012-11-14 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
M - Exercise 1,800 15,415 13.22 4.23 7,614 65,205
2012-05-29 2012-05-25 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
S - Sale -7,000 13,615 -33.96 15.86 -111,020 215,934
2012-05-18 2012-05-17 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
P - Purchase 2,000 20,615 10.74 15.69 31,380 323,449
2012-02-24 2012-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Stock Option to Buy
A - Award 9,330 9,330
2012-02-24 2012-02-22 4 SGNT Sagent Pharmaceuticals, Inc.
Common Stock
A - Award 5,220 18,615 38.97
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)